News Daiichi Sankyo launches its STING operation against cancer Daiichi Sankyo has started clinical testing of a STING agonist for cancer, a class that has been hit by safety issues and discontinued programmes.
News Mersana stung by FDA hold on STING drug Death in ph1 trial casts a pall over GSK-backed project, licensed for $100m upfront last year.
Events Partner Content STING & TLR Targeting Therapies Summit Investigating the cGAS-STING and TLR pathways
News Chiesi signs $1.9bn deal to buy KalVista and its HAE drug Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.